Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts. Show more

Location: 21 Hickory Drive, Waltham, MA, 02451, United States | Website: https://www.sionnatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

900.8M

52 Wk Range

$7.25 - $25.19

Previous Close

$20.94

Open

$20.87

Volume

51,638

Day Range

$20.12 - $20.87

Enterprise Value

504.8M

Cash

269.7M

Avg Qtr Burn

-13.98M

Insider Ownership

7.20%

Institutional Own.

93.43%

Qtr Updated

03/31/25